ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
-0.49%
US Dollar vs MXN
16.5501
-0.31%
Brent Oil
83.53
-0.08%
Bitcoin
71,360.55
7.68%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Natera Inc (NTRA)

  7. Natera Inc (NTRA) Noticias

NTRA

Natera (NTRA)

Natera Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:NTRA
FechaHoraFuenteTítuloSímboloCompañía
20/05/202415:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTRANatera Inc
17/05/202420:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTRANatera Inc
09/05/202415:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTRANatera Inc
09/05/202415:05Business WireNatera Reports First Quarter 2024 Financial ResultsNASDAQ:NTRANatera Inc
03/05/202407:00Business WireNew Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast CancerNASDAQ:NTRANatera Inc
01/05/202415:05Business WireNatera to Report its First Quarter 2024 Results on May 9NASDAQ:NTRANatera Inc
01/05/202406:00Business WireNatera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg ShortageNASDAQ:NTRANatera Inc
22/04/202407:00Business WireNatera Announces Significant Milestone with 200+ Peer-Reviewed PublicationsNASDAQ:NTRANatera Inc
11/04/202407:00Business WireNatera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney TransplantationNASDAQ:NTRANatera Inc
08/04/202407:00Business WireNatera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant RecipientsNASDAQ:NTRANatera Inc
05/04/202406:00Business WireNatera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder CancerNASDAQ:NTRANatera Inc
01/04/202407:00Business WireNatera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial CancerNASDAQ:NTRANatera Inc
18/03/202406:00Business WireNatera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal CancerNASDAQ:NTRANatera Inc
14/03/202407:00Business WireNew KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseNASDAQ:NTRANatera Inc
12/03/202407:00Business WireNatera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast CancersNASDAQ:NTRANatera Inc
07/03/202407:00Business WireNatera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS PlanNASDAQ:NTRANatera Inc
29/02/202407:00Business WireNatera to Participate in March Investor ConferencesNASDAQ:NTRANatera Inc
28/02/202415:05Business WireNatera Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:NTRANatera Inc
27/02/202407:00Business WireNatera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure TestsNASDAQ:NTRANatera Inc
26/02/202406:00Business WireMedicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast CancerNASDAQ:NTRANatera Inc
20/02/202407:00Business WireNatera Announces Fourth Quarter and Fiscal 2023 Earnings Conference CallNASDAQ:NTRANatera Inc
05/02/202407:00Business WireNew Study Validates Signatera™ in Endometrial CancerNASDAQ:NTRANatera Inc
30/01/202420:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NTRANatera Inc
30/01/202406:00Business WireNew Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung CancerNASDAQ:NTRANatera Inc
29/01/202406:00Business WireJury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past RoyaltiesNASDAQ:NTRANatera Inc
25/01/202406:00Business WireNature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal MalignanciesNASDAQ:NTRANatera Inc
22/01/202406:00PR Newswire (US)Invitae Completes Sale of Reproductive Health Assets to NateraNASDAQ:NTRANatera Inc
22/01/202406:00Business WireNatera Acquires Reproductive Health Assets from InvitaeNASDAQ:NTRANatera Inc
18/01/202407:00Business WireNatera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRCNASDAQ:NTRANatera Inc
16/01/202416:17Business WireNatera Provides Update on Ravgen TrialNASDAQ:NTRANatera Inc
 Showing the most relevant articles for your search:NASDAQ:NTRA

Su Consulta Reciente

BIT
S29033
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados